Cantor Fitzgerald assumed coverage of Insmed (INSM) with an Overweight rating and $192 price target Following a strong re-rating, Insmed has become a popular long, supported by the brensocatib launch, growing confidence in Treprostinil Palmitil Inhalation Powder, and a credible management team, the analyst tells investors in a research note. The story appears far from over as the company evolves into a diversified, respiratory-focused growth platform, and the near-term brensocatib launch, pipeline depth, and proven execution together create a compelling setup for continued momentum, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- INSM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insmed’s CEDAR Study: A Potential Game-Changer for Hidradenitis Suppurativa Treatment
- Insmed’s Phase 1 Study on TPIP Formulations: A Potential Game-Changer in Drug Delivery
- Insmed’s New Phase 3 Study: A Potential Game Changer for PH-ILD Treatment?
- Insmed price target raised to $187 from $142 at BofA